基础医学与临床 ›› 2014, Vol. 34 ›› Issue (3): 418-421.

• 短篇综述 • 上一篇    下一篇

Carfilzomib治疗复发/难治多发性骨髓瘤的临床进展

邹彬镔,石庆之   

  1. 南昌大学第二附属医院
  • 收稿日期:2013-08-27 修回日期:2013-09-24 出版日期:2014-03-05 发布日期:2014-02-27
  • 通讯作者: 石庆之 E-mail:qingzhis@sohu.com

Advances of carfilzomib in treatment of relapsed and refractory multiple myeloma

  • Received:2013-08-27 Revised:2013-09-24 Online:2014-03-05 Published:2014-02-27

摘要: Carfilzomib为2代蛋白酶体抑制剂,近期已用于复发/难治多发性骨髓瘤(RRMM)的治疗。该药对硼替佐米耐药和未接受过硼替佐米治疗的患者都有较好疗效,且不良反应可耐受。与一代蛋白酶体抑制剂硼替佐米比较,Carfilzomib引起的外周神经病变少见。

关键词: Carfilzomib, 蛋白酶体抑制剂, 多发性骨髓瘤, 复发, 难治, 抗骨髓瘤

Abstract: Carfilzomib is a second-generation selective proteasome inhibitor that has been recently used for relapse or refractory multiple myeloma(RRMM). It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.

Key words: Carfilzomib, proteasome inhibitor, multiple myeloma, relapse, refractory, anti-myeloma